Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

ET, Dow E-minis were up 89 points, or 0.2%, S&P 500 E-minis were up 12.25 points, or 0.2%, and Nasdaq 100 E-minis were up ...

U.S. stock index futures took a pause on Thursday as investors evaluated a wave of corporate earnings, while a seeming lull in the escalation of U.S. President Donald Trump's tariffs gave markets some ...